MultiHance Injection (Gadobenate Dimeglumine)

Adult dosage

This medication is administered as a bolus intravenous injection or as a slow (10 mL/min) drip intravenous injection. For liver diagnosis, it is administered at a dosage of 0.1 mL/kg (0.05 mmol/kg).

This medication may cause serious side effects in patients with severely impaired kidney function or hepatic encephalopathy; therefore, it should be used with caution. In particular, the use of contrast agents should be limited in patients with decreased renal function, and renal function tests must be performed as necessary. The administered dose must not exceed the approved dosage, and when re-administering, the previously administered contrast agent must be sufficiently eliminated. In patients who have received gadolinium contrast agents multiple times, gadolinium may accumulate in the brain; therefore, the necessity of using the contrast agent should be considered carefully. This medication should not be administered to patients with allergies to specific components, pregnant women, or patients with severely impaired kidney function. It should be administered with caution in patients with cardiovascular disease, those with a history of allergies, and in children under 18 years of age. After using this medication, various adverse reactions such as skin rashes, itching, myalgia, nausea, and headaches may occur; if such symptoms arise, the patient should inform the healthcare provider immediately. Especially in patients with reduced kidney function, there is a risk of a serious side effect known as nephrogenic systemic fibrosis (NSF), so long-term monitoring is necessary. This medication must be administered in a professional medical institution where emergency relief is possible, and the patient must be observed by healthcare personnel for a certain period after administration. Pregnant or nursing women are advised to avoid the use of this medication; if nursing, they should stop breastfeeding for at least 24 hours after administration. Elderly patients are at a higher risk of reduced kidney function, so care must be taken regarding dosage adjustments and intervals between administrations. This medication must be injected precisely into the vein without dilution before injection and should not be mixed with other medications. Any remaining solution after use should be discarded and should not be frozen during storage. When administering this medication, the patient's medical history and renal function status must be thoroughly checked, and preparations should be made to respond quickly to any adverse reactions.

Serious side effects

Hives, severe swelling (including rashes and skin puffiness), chest tightness, difficulty breathing, cold sweat, pallor, severe rashes with high fever, blisters, shedding skin, pain in oral/eye mucosa, severe allergic reactions, severe skin adverse reactions, respiratory problems (including idiopathic dyspnea, laryngeal spasms, wheezing, pulmonary congestion, pulmonary edema, laryngospasm), yellowing of the skin or eyes (jaundice), extreme lethargy in the body, liver impairment

Mild side effects

• Headache
• sensory abnormalities
• dizziness
• fainting
• abnormal olfaction
• tremors
• hypersensitivity
• elevated intracranial pressure
• hemiplegia
• visual disturbances

This medication should be stored in a sealed container that can prevent air and moisture. The appropriate storage temperature is in a cool place between 1 and 25 degrees Celsius.

Appearance

This medication is a colorless and transparent injection solution contained in a colorless and transparent vial.

Package unit

5, 10, 15, 20 milliliters / vial